PMID- 20950584
OWN - NLM
STAT- MEDLINE
DCOM- 20110705
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1807
IP  - 6
DP  - 2011 Jun
TI  - Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer 
      metabolism.
PG  - 562-7
LID - 10.1016/j.bbabio.2010.10.008 [doi]
AB  - Adenine nucleotide translocase (ANT), a mitochondrial protein that facilitates 
      the exchange of ADP and ATP across the mitochondrial inner membrane, plays an 
      essential role in cellular energy metabolism. Human ANT presents four isoforms 
      (ANT1-4), each with a specific expression depending on the nature of the tissue, 
      cell type, developmental stage and status of cell proliferation. Thus, ANT1 is 
      specific to muscle and brain tissues; ANT2 occurs mainly in proliferative, 
      undifferentiated cells; ANT3 is ubiquitous; and ANT4 is found in germ cells. ANT1 
      and ANT3 export the ATP produced by oxidative phosphorylation (OxPhos) from the 
      mitochondria into the cytosol while importing ADP. In contrast, the expression of 
      ANT2, which is linked to the rate of glycolytic metabolism, is an important 
      indicator of carcinogenesis. In fact, cancers are characterized by major 
      metabolic changes that switch cells from the normally dual oxidative and 
      glycolytic metabolisms to an almost exclusively glycolytic metabolism. When 
      OxPhos activity is impaired, ANT2 imports glycolytically produced ATP into the 
      mitochondria. In the mitochondrial matrix, the F1F0-ATPase complex hydrolyzes the 
      ATP, pumping out a proton into the intermembrane space. The reverse operations of 
      ANT2 and F1F0-ATPase under glycolytic conditions contribute to maintaining the 
      mitochondrial membrane potential, ensuring cell survival and proliferation. 
      Unlike the ANT1 and ANT3 isoforms, ANT2 is not pro-apoptotic and may therefore 
      contribute to carcinogenesis. Since the expression of ANT2 is closely linked to 
      the mitochondrial bioenergetics of tumors, it should be taken into account for 
      individualizing cancer treatments and for the development of anticancer 
      strategies.
CI  - Copyright (c) 2010 Elsevier B.V. All rights reserved.
FAU - Chevrollier, Arnaud
AU  - Chevrollier A
AD  - CNRS, UMR6214, F-49000 Angers, France. archevrollier@chu-angers.fr
FAU - Loiseau, Dominique
AU  - Loiseau D
FAU - Reynier, Pascal
AU  - Reynier P
FAU - Stepien, Georges
AU  - Stepien G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101013
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Adenine Nucleotide Translocator 2)
RN  - 0 (Isoenzymes)
RN  - 0 (Mitochondrial Proteins)
SB  - IM
MH  - Adenine Nucleotide Translocator 2/genetics/metabolism/*physiology
MH  - Animals
MH  - Energy Metabolism/physiology
MH  - Humans
MH  - Isoenzymes/genetics/metabolism/physiology
MH  - Mitochondria/*enzymology/metabolism/pathology
MH  - Mitochondrial Proteins/genetics/metabolism/physiology
MH  - Models, Biological
MH  - Neoplasms/enzymology/genetics/*metabolism
MH  - Oxidative Phosphorylation
EDAT- 2010/10/19 06:00
MHDA- 2011/07/06 06:00
CRDT- 2010/10/19 06:00
PHST- 2010/07/13 00:00 [received]
PHST- 2010/10/05 00:00 [revised]
PHST- 2010/10/05 00:00 [accepted]
PHST- 2010/10/19 06:00 [entrez]
PHST- 2010/10/19 06:00 [pubmed]
PHST- 2011/07/06 06:00 [medline]
AID - S0005-2728(10)00716-4 [pii]
AID - 10.1016/j.bbabio.2010.10.008 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2011 Jun;1807(6):562-7. doi: 10.1016/j.bbabio.2010.10.008. 
      Epub 2010 Oct 13.